HOME >> MEDICINE >> NEWS
Positive results more likely from industry-funded breast cancer trials

CHAPEL HILL Industry-funded studies of breast cancer therapies are more likely to report positive results than non-pharmaceutical funded studies, researchers from the University of North Carolina at Chapel Hill and the Dana Farber Cancer Institute have found. In addition, significant differences exist in the design and nature of clinical trials supported by the pharmaceutical industry compared to trials without industry involvement.

Published online Feb. 26 in CANCER, the journal of the American Cancer Society, the study explores the impact of pharmaceutical-company involvement on breast cancer clinical trial design and outcome. Drug-industry investment in research now exceeds the operating budget of the National Institutes of Health and previous studies have examined the impact on other areas of clinical medicine, but not breast cancer.

Our study shines a flashlight on the issue of the rising role and potential impact of the pharmaceutical industry on breast cancer research and highlights important questions that need to be addressed through further research, said Dr. Jeffrey Peppercorn, assistant professor of medicine in UNC School of Medicines division of hematology and oncology and a member of the UNC Lineberger Comprehensive Cancer Center.

The significance of our study is not to say that the drug industry does anything wrong they are excellent at developing new therapies, and there are many recent examples in breast cancer research. But if more and more research is funded by drug companies, then the limited amount of funding coming from other sources may need to be directed to address other questions, Peppercorn said.

The researchers reviewed all breast cancer clinical trials published in 10 English-language medical journals in the years 1993, 1998 and 2003. They focused their formal statistical analysis on the 2003 trials because the identification of industry funded or non-industry funded research was likely more
'"/>

Contact: Dianne Shaw
dgs@med.unc.edu
919-966-7834
University of North Carolina School of Medicine
26-Feb-2007


Page: 1 2

Related medicine news :

1. M. D. Anderson reports first drug activity in T315I-Positive CML, ALL and JAK-2-Positive MPD
2. Positive parenting helps encourage healthy sun habits in children
3. Positive results for ACRUXs lead product in US Phase 3 trial
4. Positive outcome of Medicare drug benefit
5. Positive study results for methylphenidate transdermal system
6. Positive study results for methylphenidate transdermal system
7. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
8. GSKs Pazopanib shows positive results in patients with advanced renal cell carcinoma
9. GSKs Pazopanib shows positive results in patients with advanced RCC and ovarian cancer
10. Targeted, oral agent Enzastaurin shows favorable results
11. Childhood obesity intervention shows promising results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2019)... ... 22, 2019 , ... Isagenix International , a global ... of business and transformed lives with the limited-edition Birthday Cake Flavor IsaLean® ... last, the meal replacement protein shake features sprinkles made with colors from natural ...
(Date:3/20/2019)... ... March 20, 2019 , ... American Family Care (AFC), the nation's leading provider ... new and existing franchisees access to up to $30 million in debt capital to ... has pioneered the concept of urgent care and expanded its footprint to become one ...
(Date:3/20/2019)... ... March 20, 2019 , ... GRM Information Management, a leading provider of content ... conference in Austin, Texas on March 25 and 26. , Texas HIMSS 2019 ... healthcare information management solutions . , GRM offers a range of digital solutions ...
(Date:3/20/2019)... ... March 20, 2019 , ... Vera Whole Health , ... paper that examines how on-site clinics keep employees healthy and drive down the total ... employers understand the benefits of adopting on-site clinics. , The Vera white paper ...
(Date:3/20/2019)... ... March 20, 2019 , ... ... Crominex®3+, a composition of trivalent chromium chloride combined with extracts of amla and ... This newly granted patent, along with 7 clinical studies on Crominex®3+, establish this ...
Breaking Medicine News(10 mins):
(Date:3/20/2019)... , ... March 20, 2019 , ... ... companies. A leading third-party retirement plan administration firm specializing in quality retirement plan ... As CEO Brad Lankford said, “Latitude is as much an idea as it ...
(Date:3/20/2019)... SOLANA BEACH, Calif. (PRWEB) , ... ... ... the world’s fastest-growing digital marketplace for outsourced research services and products, announced ... researchers an array of HEOR services. The Canadian-based company offers RWE research, ...
(Date:3/19/2019)... ... March 19, 2019 , ... AltaPointe ... services’ patients Stay Active & Independent for Life (SAIL). At the core of ... and fitness can help adults stay active and reduce their chances of falling. ...
Breaking Medicine Technology:
Cached News: